CRIS
Curis, Inc.
There isn't enough reported data to score CRIS yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
CRIS Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Weak | |
| Unavailable |
CRIS's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CRIS PE Valuation
CRIS has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CRIS Forward outlook
There aren't enough analyst estimates for CRIS to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CRIS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$2.02 | +$92.58 |
| Q1 2026 | -$11.60 | +$110.00 |
| Q4 2025 | -$11.60 | +$126.00 |
| Q3 2025 | -$70.40 | +$85.80 |
| Q2 2025 | -$94.60 | +$70.20 |
| Q1 2025 | -$121.60 | +$50.60 |
| Q4 2024 | -$137.60 | +$41.60 |
| Q3 2024 | -$156.20 | +$30.40 |
CRIS is still losing money, but far less than before: $2.02 per share over the past year, against $388.00 at its worst in late 2019.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CRIS on earnings quality, reporting a profit while its opponent remains loss making.
CRIS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $1.1M | -66% |
| Q3 2025 | $3.2M | +8.4% |
| Q2 2025 | $2.7M | +8% |
| Q1 2025 | $2.4M | +14% |
| Q4 2024 | $3.3M | +24% |
| Q3 2024 | $2.9M | +3.5% |
| Q2 2024 | $2.5M | +16% |
| Q1 2024 | $2.1M | -9.2% |
CRIS's revenue has slid since its 2024 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 1724% | +1993 points |
| Q3 2025 | -218% | +143 points |
| Q2 2025 | -300% | +191 points |
| Q1 2025 | -427% | +171 points |
| Q4 2024 | -269% | +184 points |
| Q3 2024 | -361% | +76 points |
| Q2 2024 | -491% | +61 points |
| Q1 2024 | -598% | -92 points |
CRIS's operating margin was 1724% last quarter, up 1993 points from the same quarter a year ago, near the top of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CRIS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
CRIS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$9.6M | -$1.6M |
| Q1 2026 | -$9M | -$1.7M |
| Q4 2025 | -$6.4M | +$2.9M |
| Q3 2025 | -$5.6M | +$367K |
| Q2 2025 | -$8M | +$3.1M |
| Q1 2025 | -$7.3M | +$6M |
| Q4 2024 | -$9.3M | +$926K |
| Q3 2024 | -$5.9M | +$2.2M |
CRIS has burned cash in almost every quarter: −$31M over the past year, against −$30M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CRIS on cash generation, producing positive trailing cash flow while its opponent burns cash.
CRIS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +121% | +1.2M shares |
| 1 year | +238% | +1.5M shares |
| 3 years | +784% | +1.9M shares |
| 5 years | +1187% | +2M shares |
| Available history | +2473% | +2.1M shares |
CRIS has 2M diluted shares, up 238% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CRIS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CRIS Net Leverage
CRIS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CRIS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.9 | Oversold |
| Stochastic | 7.6 | Oversold |
CRIS's weekly RSI is 24 (oversold) and its Stochastic is 8 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CRIS PE vs Healthcare Sector
CRIS has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CRIS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.65 | 12% below |
| 20 week MA | $2.20 | 74% below |
| 50 week MA | $10.3 | 94% below |
| 100 week MA | $26.8 | 98% below |
| 200 week MA | $118.4 | 100% below |
CRIS is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CRIS on trend strength, trading above more of its moving averages.
CRIS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $620.0 | $3,180.0 | +413% |
| 2021 | $3,180.0 | $2,072.0 | -35% |
| 2022 | $2,072.0 | $197.4 | -90% |
| 2023 | $197.4 | $255.0 | +29% |
| 2024 | $255.0 | $65.0 | -75% |
| 2025 | $65.0 | $21.2 | -67% |
| 2026 YTD | $21.2 | $0.57 | -97% |
CRIS's yearly returns have swung widely, from +413% in 2020 to −90% in 2022. It's down 97% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CRIS on returns for 2026, with the stronger performance.